| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.09.01 | 50.00 | 15.190 | 15.140 | 758.13 | | 2025.08.29 | 22.80 | 15.370 | 15.210 | 348.33 | | 2025.08.28 | 30.00 | 16.000 | 15.810 | 477.69 | | 2025.07.25 | 20.00 | 17.280 | 17.020 | 343.33 | | 2025.07.24 | 20.00 | 17.300 | 17.240 | 345.45 | | 2025.07.23 | 20.00 | 17.560 | 17.500 | 351.09 | | 2025.07.22 | 20.00 | 17.200 | 17.180 | 343.67 | | 2025.07.21 | 20.00 | 17.120 | 17.060 | 342.07 | | 2025.07.18 | 20.00 | 16. ...

智通财经APP讯，蒙牛乳业(02319)发布公告，于2025年9月1日斥资758.13万港元回购50万股股份。 该信 息由智通财经网提供 ...

格隆汇9月1日丨蒙牛乳业(02319.HK)发布公告，2025年9月1日耗资758万港元回购50万股。 ...

蒙牛乳业(02319)发布公告，于2025年9月1日斥资758.13万港元回购50万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國蒙牛乳業有限公司 呈交日期： 2025年9月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02319 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前 ...

建银国际发布研报称，蒙牛乳业(02319)拥有强劲现金流，可为2025至2027年间50%股息分派比率提供支 持，而持续股份回购亦可支持估值。该行调整蒙牛目标价至20.7港元，维持"跑赢大市"评级。 ...

智通财经APP获悉，建银国际发布研报称，蒙牛乳业(02319)拥有强劲现金流，可为2025至2027年间50% 股息分派比率提供支持，而持续股份回购亦可支持估值。该行调整蒙牛目标价至20.7港元，维持"跑赢 大市"评级。 ...

CHINA MENGNIU DAIRY COMPANY LIMITED 中國蒙牛乳業有限公司* （於開曼群島注册成立的有限公司） （股份代號：2319） 董事名單與其角色和職能 中國蒙牛乳業有限公司董事會（「董事會」）成員載列如下： 執行董事 高飛先生（總裁） 沈新文先生 王燕女士 非執行董事 慶立軍先生（主席） 孟凡傑先生 Lillie Li VALEUR 女士 獨立非執行董事 葉禮德先生 李恒健先生 葛俊先生 董事會已設立五個董事委員會。下表載有各董事會成員在這些委員會中擔任的職位。 | 董事 | 董事委員會 | 審核委員會 | 提名委員會 | 薪酬委員會 | 戰略及發展 | 可持續發展 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 委員會 | 委員會 | | 高飛先生 | | | | | 成員 | 成員 | | 沈新文先生 | | | | | 成員 | | | 王燕女士 | | | | | | 成員 | | 慶立軍先生（主席） | | | 委員會主席 | | 委員會主席 | | | 孟凡傑先生 | | | | | 成員 | | | L ...

Core Insights - Mengniu Group showcased its self-developed probiotic strain Lc19 at the International Nutrition Conference, revealing a new mechanism for regulating blood sugar through the microbial tryptophan-cholic acid (TRP-CA) pathway, providing a "Chinese solution" for global blood sugar health management [1][5] - The research was published in the prestigious journal "Cell," marking the first application-based achievement in food science to be included in this journal, highlighting Mengniu's significant progress in overcoming the "bottleneck" issues in probiotic technology and establishing a "Chinese core" in the dairy industry [3][6] Industry Context - China has 233 million diabetes patients, accounting for 13.7% of the total population, the highest scale and proportion globally. Mengniu's innovation addresses this public health challenge by developing the Lc19 strain, which activates human receptors to promote GLP-1 and insulin secretion, thus improving blood sugar stability [5][6] - Mengniu's breakthrough in the Lc19 strain is part of a broader strategy to tackle the lack of high-quality domestic probiotics and outdated processing technologies in China's dairy industry, positioning the company as a leader in scientific innovation [9] Research and Development Achievements - Since 2010, Mengniu has established a proprietary resource library with over 18,000 strains, achieving a "zero breakthrough" in independent strain development. The company has received multiple prestigious awards for its patented strains, including the National Science and Technology Progress Award [9][11] - Mengniu's R&D investment has been growing at an annual rate of 13%, projected to reach 513 million yuan in 2024, with a focus on building a global innovation network and nine R&D bases worldwide [11] Product Development and Market Strategy - The Lc19 strain has been successfully applied in the market with the launch of the Youruian Sugar Shield probiotic powder, which combines Lc19 with other patented strains and natural plant extracts to meet blood sugar control needs [6][12] - Mengniu is expanding its product offerings to include low-GI products, senior nutrition, special medical nutrition, and sports nutrition, aiming to meet diverse health needs across different consumer segments [14][16]

Summary of Key Points Core Viewpoint - On August 29, 25 Hong Kong-listed companies conducted share buybacks, totaling 17.2021 million shares and an aggregate amount of 869 million HKD [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 919,000 shares for 550 million HKD, with a highest price of 605.000 HKD and a lowest price of 594.500 HKD, bringing its total buyback amount for the year to 45.549 billion HKD [1][2]. - China Hongqiao repurchased 8.9235 million shares for 227 million HKD, with a highest price of 25.440 HKD, totaling 3.911 billion HKD in buybacks for the year [1][2]. - Hang Seng Bank repurchased 210,000 shares for 23.5169 million HKD, with a highest price of 112.500 HKD and a lowest price of 111.500 HKD, totaling 479.2213 million HKD in buybacks for the year [1][2]. Group 2: Notable Buybacks - The largest buyback amount on August 29 was from Tencent Holdings at 550 million HKD, followed by China Hongqiao at 227 million HKD [1][2]. - In terms of share quantity, China Hongqiao led with 8.9235 million shares repurchased, followed by Weigao Group and MGM China with 1.26 million and 1 million shares, respectively [1][2]. Group 3: First-Time Buybacks - Companies such as NetDragon and Greentown Management conducted their first buybacks of the year on this date [2].